This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Renal cancer	Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)	<p>Studies in patient samples and in mice suggest inhibiting CSF1R could help treat renal cell carcinoma (RCC). In renal biopsy samples, CSF1R expression was greater in RCC tissue than in normal kidney tissue. In a mouse model of RCC, a CSF1R inhibitor decreased macrophage infiltration and tumor growth compared with vehicle control. Next steps include testing the safety of CSF1R inhibition and comparing its effectiveness with that of other cancer therapies. PLX5622, a small molecule CSF1R inhibitor from Daiichi Sankyo Co. Ltd., is in Phase I testing to treat rheumatoid arthritis (RA).</p> <p>SciBX 4(45); doi:10.1038/scibx.2011.1267 Published online Nov. 17, 2011</p>	Unpatented; licensing status unavailable	<p>Menke, J. <i>et al. Cancer Res.</i>; published online Nov. 3, 2011; doi:10.1158/0008-5472.CAN-11-1232 Contact: Julia Menke, Johannes Gutenberg University Mainz, Mainz, Germany e-mail: menkj005@gmx.de</p>